These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 15942317

  • 21. Becaplermin gel (PDGF-BB) as topical wound therapy. Plastic Surgery Educational Foundation DATA Committee.
    Ladin D.
    Plast Reconstr Surg; 2000 Mar; 105(3):1230-1. PubMed ID: 10724287
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N.
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [Abstract] [Full Text] [Related]

  • 23. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial.
    Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D, OASIS Venus Ulcer Study Group.
    J Vasc Surg; 2005 May; 41(5):837-43. PubMed ID: 15886669
    [Abstract] [Full Text] [Related]

  • 24. Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers.
    Gilligan AM, Waycaster CR, Motley TA.
    Wound Repair Regen; 2015 May; 23(3):353-60. PubMed ID: 25810233
    [Abstract] [Full Text] [Related]

  • 25. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S.
    Clin Podiatr Med Surg; 2002 Oct; 19(4):483-91. PubMed ID: 12471856
    [Abstract] [Full Text] [Related]

  • 26. An extracellular matrix graft (Oasis® wound matrix) for treating full-thickness pressure ulcers: A randomized clinical trial.
    Brown-Etris M, Milne CT, Hodde JP.
    J Tissue Viability; 2019 Feb; 28(1):21-26. PubMed ID: 30509850
    [Abstract] [Full Text] [Related]

  • 27. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.
    Guzman-Gardearzabal E, Leyva-Bohorquez G, Salas-Colín S, Paz-Janeiro JL, Alvarado-Ruiz R, García-Salazar R.
    Adv Ther; 2000 Feb; 17(4):184-9. PubMed ID: 11185057
    [Abstract] [Full Text] [Related]

  • 28. Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer HealingChanges in Wound Surface Area.
    Waycaster CR, Gilligan AM, Motley TA.
    J Am Podiatr Med Assoc; 2016 Jul; 106(4):273-82. PubMed ID: 27049838
    [Abstract] [Full Text] [Related]

  • 29. A Prospective, Randomized, Blinded, Controlled Trial Comparing Transdermal Continuous Oxygen Delivery to Moist Wound Therapy for the Treatment of Diabetic Foot Ulcers.
    Driver VR, Reyzelman A, Kawalec J, French M.
    Ostomy Wound Manage; 2017 Apr; 63(4):12-28. PubMed ID: 28448266
    [Abstract] [Full Text] [Related]

  • 30. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration.
    O'Meara S, Cullum N, Majid M, Sheldon T.
    Health Technol Assess; 2000 Apr; 4(21):1-237. PubMed ID: 11074391
    [Abstract] [Full Text] [Related]

  • 31. Comparing the standard surgical dressing with dehydrated amnion and platelet-derived growth factor dressings in the healing rate of diabetic foot ulcer: A randomized clinical trial.
    Mohammadi Tofigh A, Tajik M.
    Diabetes Res Clin Pract; 2022 Mar; 185():109775. PubMed ID: 35149167
    [Abstract] [Full Text] [Related]

  • 32. Healing and preventing the diabetic foot wound: where technology, economics and common sense converge.
    Armstrong DG.
    Indian J Med Sci; 2007 Jun; 61(6):324-5. PubMed ID: 17558094
    [No Abstract] [Full Text] [Related]

  • 33. Topical treatment of hypertensive leg ulcers with platelet-derived growth factor-BB: a randomized controlled trial.
    Senet P, Vicaut E, Beneton N, Debure C, Lok C, Chosidow O.
    Arch Dermatol; 2011 Aug; 147(8):926-30. PubMed ID: 21482863
    [Abstract] [Full Text] [Related]

  • 34. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group.
    Smiell JM.
    Am J Surg; 1998 Aug; 176(2A Suppl):68S-73S. PubMed ID: 9777975
    [Abstract] [Full Text] [Related]

  • 35. Clinical trial report stirs debate.
    Magee G, Ovington LG.
    Adv Skin Wound Care; 2006 Mar; 19(2):64; author reply 64, 67. PubMed ID: 16557046
    [No Abstract] [Full Text] [Related]

  • 36. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management.
    Boykin JV.
    Adv Skin Wound Care; 2000 Mar; 13(4 Pt 1):169-74. PubMed ID: 11075012
    [Abstract] [Full Text] [Related]

  • 37. [New developments in the treatment of diabetic foot ulcers].
    Bakker K, Schaper NC.
    Ned Tijdschr Geneeskd; 2000 Feb 26; 144(9):409-12. PubMed ID: 10719543
    [Abstract] [Full Text] [Related]

  • 38. Cellular versus acellular matrix devices in the treatment of diabetic foot ulcers: Interim results of a comparative efficacy randomized controlled trial.
    Tchanque-Fossuo CN, Dahle SE, Lev-Tov H, West KIM, Li CS, Rocke DM, Isseroff RR.
    J Tissue Eng Regen Med; 2019 Aug 26; 13(8):1430-1437. PubMed ID: 31070860
    [Abstract] [Full Text] [Related]

  • 39. Adenosine A2A receptor agonists promote more rapid wound healing than recombinant human platelet-derived growth factor (Becaplermin gel).
    Victor-Vega C, Desai A, Montesinos MC, Cronstein BN.
    Inflammation; 2002 Feb 26; 26(1):19-24. PubMed ID: 11936752
    [Abstract] [Full Text] [Related]

  • 40. Hydrogel dressings for healing diabetic foot ulcers.
    Dumville JC, O'Meara S, Deshpande S, Speak K.
    Cochrane Database Syst Rev; 2011 Sep 07; (9):CD009101. PubMed ID: 21901730
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.